Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > The Call
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(296)
•••
Comment by inthnoon Nov 03, 2023 2:57pm
114 Views
Post# 35716386

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:The Call

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:The Call
Telling it like it is is not trying to drive the price down. I would really like added shareholder value that the company is always talking about and down 80% from the consolidation from around 10 dollars and 15 million shares to just over 2 dollars and 70 million shares is not adding shareholder value.
We have been told next year since mbc 213 7 years ago. Give the shareholders some respect and tell them what is actually going on BD wise and what is happening with the 90 days and why timelines are being pushed out.
People can bash or cheer all they want but neither are making a difference as to what is actually going on with the company and the lack of what they are telling us. Comes down to a little bit of respect to those that are paying the salaries.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities